Hypertension Diagnostics Stock EBITDA

HDIIDelisted Stock  USD 0  0.0008  38.10%   
Hypertension Diagnostics fundamentals help investors to digest information that contributes to Hypertension Diagnostics' financial success or failures. It also enables traders to predict the movement of Hypertension Pink Sheet. The fundamental analysis module provides a way to measure Hypertension Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hypertension Diagnostics pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Hypertension Diagnostics Company EBITDA Analysis

Hypertension Diagnostics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Hypertension Diagnostics EBITDA

    
  72.29 K  
Most of Hypertension Diagnostics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypertension Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Hypertension Diagnostics reported earnings before interest,tax, depreciation and amortization of 72.29 K. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 100.0% higher than that of the company.

Hypertension EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hypertension Diagnostics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hypertension Diagnostics could also be used in its relative valuation, which is a method of valuing Hypertension Diagnostics by comparing valuation metrics of similar companies.
Hypertension Diagnostics is currently under evaluation in ebitda category among its peers.

Hypertension Fundamentals

About Hypertension Diagnostics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Hypertension Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hypertension Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hypertension Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Hypertension Pink Sheet

If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Technical Analysis
Check basic technical indicators and analysis based on most latest market data